Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) reports the U.S. District Court for the Southern District of New York has issued a favorable set of claim construction rulings in the Company s patent infringement lawsuit against Sandoz Inc./Momenta Pharmaceuticals, Inc. and Mylan/Natco regarding Teva s multiple sclerosis (MS) product, Copaxone.
The Court adopted all relevant Teva claim construction interpretations and rejected all of the claim construction interpretations put forth by Sandoz/Momenta and Mylan/Natco. In addition, the Court denied Mylan s motion for summary judgment that the patents at issue are invalid for indefiniteness.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.